Xenetic Biosciences Reports 2025 Financial Results

Biopharmaceutical company focused on immuno-oncology technologies for difficult-to-treat cancers

Mar. 13, 2026 at 2:10pm

Got story updates? Submit your updates here. ›

Xenetic Biosciences, Inc. (NASDAQ:XBIO), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies, reported its financial results for the year ended December 31, 2025. The company expanded and presented preclinical and translational evidence supporting neutrophil extracellular traps (NETs) as drivers of cancer progression and highlighting the therapeutic potential of Deoxyribonuclease (DNase)-based interventions. Xenetic also progressed investigator-initiated exploratory studies in Israel evaluating DNase I in combination with standard-of-care and immunotherapy platforms, including for pancreatic ductal adenocarcinoma (PDAC) and large B-cell lymphoma (LBCL).

Why it matters

Xenetic's focus on advancing its DNase-based technology toward Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors represents a promising approach to addressing difficult-to-treat cancers. The company's preclinical and translational research linking NETs to cancer progression and the therapeutic potential of DNase-based strategies could lead to new treatment options for patients.

The details

During 2025, Xenetic completed preclinical studies evaluating DNase I in combination with chemotherapy, immunotherapies and CAR-T approaches across both solid and hematologic cancer models. The data from these studies are informing the company's ongoing translational work and manufacturing activities as it progresses toward a U.S. Investigational New Drug (IND) submission. Xenetic ended the year with $7.9 million in cash, representing an increase of $1.7 million compared to the prior year-end, primarily due to net proceeds from a public offering.

  • Xenetic reported its financial results for the year ended December 31, 2025.

The players

Xenetic Biosciences, Inc.

A biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers.

James Parslow

Interim Chief Executive Officer and Chief Financial Officer of Xenetic.

Got photos? Submit your photos here. ›

What they’re saying

“During 2025, we continued to advance our DNase-based technology toward Phase 1 clinical development while making steady progress across scientific, operational and strategic fronts.”

— James Parslow, Interim Chief Executive Officer and Chief Financial Officer

What’s next

Xenetic continues to advance its DNase-based technology toward Phase 1 clinical development and plans to submit an Investigational New Drug (IND) application in the U.S.

The takeaway

Xenetic's focus on developing its DNase-based immuno-oncology technology represents a promising approach to addressing difficult-to-treat cancers. The company's progress in preclinical and translational research, as well as its investigator-initiated studies, position it well to potentially bring new treatment options to patients.